What is 503B Compounding

Specific to Drug Compounding: A 503B facility is a specific type of pharmaceutical compounding operation. It's a designation created by the FDA (Food and Drug Administration) under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) after the 2012 New England Compounding Center (NECC) meningitis outbreak.

Large Batch Production: 503B facilities are designed to produce large batches of compounded medications without requiring patient-specific prescriptions. They can sell these medications to healthcare facilities (hospitals, clinics, etc.) for office use.

High Regulatory Standards: They are subject to significantly stricter FDA oversight than traditional compounding pharmacies (known as 503A pharmacies). This includes complying with Current Good Manufacturing Practices (CGMP) regulations, which are typically applied to traditional drug manufacturers. They undergo regular FDA inspections and are required to report their product lists and any adverse events to the FDA.

Purpose: 503B facilities play a critical role in addressing drug shortages and providing medications that may not be commercially available from large manufacturers (e.g., specific concentrations, formulations without certain allergens). They bridge the gap between traditional pharmacies and large drug manufacturers.

Growth: The U.S. compounding pharmacies market was valued at USD 6.31 billion in 2024 and is projected to reach USD 10.76 billion by 2033, growing at a CAGR of 6.1% from 2024 to 2033

503B Sales Capabilities

Our management team has in-depth experience managing and servicing the 503A and 503B pharmaceutical compounding industry

​

We have experience building operations from $10 million to $500 million in revenue

​